• 1
    Fruton JS, Simmonds S. General Biochemistry. New york: Wiley J, 1953.
  • 2
    Furlan M. Specificity of intracellular acid proteinases for the hydrolysis of proteins. Enzymologia 1966; 31: 922.
  • 3
    Furlan M, Jericijo M. Protein catabolism in thymus nuclei. I. Hydrolysis of nucleoproteins by proteases present in calf-thymus nuclei. Biochim Biophys Acta 1967; 147: 13544.
  • 4
    Perret BA, Furlan M, Beck EA. Studies on factor VIII-related protein. II. Estimation of molecular size differences between factor VIII multimers. Biochim Biophys Acta 1979; 578: 16474.
  • 5
    Furlan M, Perret BA, Beck EA. Von Willebrand activity of low molecular weight human factor VIII increases by binding to gold granules. Br J Haematol 1981; 45: 2426.
  • 6
    Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor: cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest 1986; 77: 94751.
  • 7
    Battle J, Lopez Fernandez MF, Campos M, Justica B, Berges C, Navarro JL, Diaz Cremades JM, Kasper CK, Dent JA, Ruggeri ZM, Zimmerman TS. The heterogeneity of type IIA von Willebrand's disease: studies with protease inhibitors. Blood 1986; 68: 120712.
  • 8
    Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factors multimers resulting from proteolysis of the constituent subunit. J Clin Invest 1991; 88: 77482.
  • 9
    Furlan M, Robles R, Affolter D, Meyer D, Baillod P, Lämmle B. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA 1993; 90: 75037.
  • 10
    Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990; 87: 630610.
  • 11
    Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994; 83: 21719.
  • 12
    Furlan M, Stieger J, Beck EA. Exposure of platelet binding sites in von Willebrand factor by adsorption onto polystyrene latex particles. Biochim Biophys Acta 1987; 924: 2737.
  • 13
    Slayter H, Loscalzo J, Bockenstedt P, Handin RI. Native conformation of human von Willebrand protein. Analysis by electron microscopy and quasi-elastic light scattering. J Biol Chem 1985; 260: 855963.
  • 14
    Van Mourik JA, Bouma BN, LaBruyere WT, De Graaf S, Mochtar IA. Factor VIII, a series of homologous oligomers and a complex of two proteins. Thromb Res 1976; 4: 15564.DOI: 10.1016/0049-3848(74)90211-4
  • 15
    Bouma BN, Van Mourik JA, De Graaf S, Hardijk-Hos JM, Sixma JJ. Immunologic studies on human factor VIII (anti-hemophilic factor, AHF) components produced by low-ionic-strength dialysis. Blood 1976; 47: 25364.
  • 16
    Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 422334.
  • 17
    Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996; 87: 423544.
  • 18
    Lankhof H, Damas C, Schiphorst ME, Ijsseldijk MJW, Bracke M, Furlan M, Tsai HM, De Groot PG, Sixma JJ. Von Willebrand factor without the A2 domain is resistant to proteolysis. Thromb Haemost 1997; 77: 100813.
  • 19
    Gerritsen HE, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 2001; 98: 165461.
  • 20
    Gerritsen H, Turecek P, Schwarz HP, Lämmle B, Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 13869.
  • 21
    Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986; 78: 145661.
  • 22
    Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 14325.
  • 23
    Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097103.
  • 24
    Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81: 813.
  • 25
    Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998; 91: 283946.
  • 26
    Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic–uremic syndrome. N Engl J Med 1998; 339: 157884.DOI: 10.1056/NEJM199811263392202
  • 27
    Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 158594.DOI: 10.1056/NEJM199811263392203
  • 28
    Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 48894.DOI: 10.1038/35097008
  • 29
    Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 40339.
  • 30
    Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589600.DOI: 10.1056/NEJMra020528
  • 31
    Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001; 14: 43754.DOI: 10.1053/beha.2001.0142